Navigation Links
Risk assessment tool not reliable predictor for some women at high risk of breast cancer
Date:11/5/2008

ROCHESTER, Minn. -- A statistical model commonly used to predict the risk of breast cancer in women was not accurate when used to evaluate women with atypical hyperplasia, according to a new Mayo Clinic study published in the Oct. 14, 2008, issue of the Journal of Clinical Oncology. Atypical hyperplasia (atypia) describes breast tissue with an increased growth of abnormal cells that might become cancerous.

The Gail model calculates probabilities that a woman will develop invasive breast cancer during the next five years, and by age 90. The model has come to be called by the name of its developer, National Cancer Institute researcher Mitchell Gail, M.D., Ph.D. Its original purpose was to identify groups of high-risk women for participation in breast cancer chemoprevention studies. But the model has since been used in clinical settings to counsel individuals about their risk of developing breast cancer. Predicting risk at an individual level is much more challenging than when risks can be averaged across groups.

"The assumption has always been that this model works well in women with atypia, but this had never been validated," says Shane Pankratz, Ph.D., Mayo Clinic statistician and a lead investigator in the study. "We found that, for the group of women with atypia, the model predicted significantly fewer invasive breast cancers than were actually observed, and we also observed that the model was not able to reliably identify the women who were actually at higher risk of developing breast cancer."

The Gail model considers the woman's family history of breast cancer, her age, and her ages at the onset of menstruation and at first live birth, as well as the number of breast biopsies undergone and presence of atypical hyperplasia found in biopsies. About 5 percent of women who undergo biopsies for suspicious lumps or other breast concerns have atypia. About 25 percent of those with atypia will develop cancer within 25 years.

Mayo Clinic researchers tested the Gail model in 331 women with atypia who had benign breast biopsies at Mayo Clinic between 1967 and 1991. Of these women, 58 developed cancer during an average of 13.7 years of follow-up. In contrast, the model predicted that 34.9 women would develop breast cancer in that period.

Using these and other data, researchers also calculated the model's performance for individuals using the concordance statistic (c-statistic), which reflects how closely the actual timing of breast cancer events aligned with model predictions. A c-statistic of 0.5 is observed if the predictions are no better than random chance; a c-statistic of 1.0 is observed if the predictions are perfectly concordant with the actual outcomes. In this study, the c-statistic was 0.5, reflecting that the Gail model worked no better than a coin flip in predicting which of the women with atypia would develop invasive breast cancer.

When assessed across other groups of women without respect to the presence of atypia, the Gail model typically performs better. In that setting, it has been shown to predict approximately the same number of breast cancers that later occur.

Lynn Hartmann, M.D., Mayo Clinic oncologist and co-investigator on the study, says that there is strong interest in predicting breast cancer risk. For example, the Gail model, posted on the National Cancer Institute's Web site (http://www.cancer.gov/bcrisktool/), attracts 25,000 viewers each month.

"Doctors counsel women at high risk to have more frequent or intensive surveillance or to consider chemoprevention strategies such as tamoxifen or raloxifene," says Dr. Hartmann. "When making such decisions, women and their physicians must have highly reliable risk estimates."

Researchers are pursuing other avenues to better predict individual risk. Previously, Mayo Clinic researchers found that women with multiple sites of cellular atypia in a breast biopsy have significantly increased risk of developing breast cancer. In a study published earlier this year, Mayo researchers found that women whose atypia tissues express COX-2 enzymes were more likely to develop breast cancer, and the higher the COX-2 levels, the higher the risk.


'/>"/>

Contact: Karl Oestreich
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome
2. Personality can hamper a physicians assessment of depression
3. Simple, inexpensive and objective tools for the assessment of mucosal inflammation: fecal markers
4. California Dental Association Foundation Launches New Dental Risk Assessment Campaign
5. Notice of Proposed Rulemaking on U.S. Department of Labors Risk Assessment Procedures Published in Federal Register
6. DIA Conference to Provide New Paradigms in Evidence-Based Medicine and Health Technology Assessment
7. Risk assessment plays key role in long-term treatment of breast cancer
8. InfoLogix Launches Strategic Mobility Assessment Service for Hospitals
9. The Supports Intensity Scale Assessment Can be Used to Build Robust Funding Methods for Developmental Disability Services, New Research Reveals
10. Fox Learning Systems Selects Prymaks Discovery-180(TM) Technology Assessment to Guide Search for New LMS
11. Combined Insurance Provides Needs Assessment Checklist to Help Consumers Evaluate Their Current Supplemental Health Insurance Coverage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2017)... PA (PRWEB) , ... May 29, 2017 , ... The ... simple question: How do doctors determine if someone is cured? The virus has a ... most expensive and time-consuming tests. , Scientists at the University of Pittsburgh’s Graduate School ...
(Date:5/28/2017)... ... ... Viewers likely know Rob Lowe from such 80s hits as St. Elmo’s Fire ... NBC’s The West Wing and Parks and Recreation. But recently, Lowe’s leant his talents ... spotlight on important modern-day issues that face today’s society. One of the most recent ...
(Date:5/27/2017)... ... May 27, 2017 , ... Most us are familiar ... a new study from the Osteoarthritis Initiative shows that certain people who ... Knowing this in advance may give doctors the opportunity to treat patients before the ...
(Date:5/26/2017)... ... May 26, 2017 , ... Amir Qureshi, MD is the first physician in ... cord stimulation system. The Nuvectra™ Algovita SCS System has been FDA approved as a ... first in Arkansas to introduce the most powerful SCS system and the only stretchable ...
(Date:5/26/2017)... ... May 26, 2017 , ... On May 24, the Congressional Budget Office (CBO) ... House on May 4, would result in 23 million Americans losing their health insurance ... 2010 Patient Protection and Affordable Care Act (ACA). , “It is clear from ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)... VALLEY COTTAGE, N.Y. , May 22, 2017 ... natural antiviral treatment Gene-Eden-VIR/Novirin, announces the launch of ... in plain English, the results of a clinical ... after one year treatment with Gene-Eden-VIR/Novirin in individuals ... is important to note that there are no ...
(Date:5/18/2017)... -- Bayer announced today that the latest research from across ... 53 rd Annual Meeting of the American Society ... Chicago . The ... and thyroid cancers, as well as lymphomas, and includes ... of copanlisib in patients with relapsed or refractory follicular ...
(Date:5/12/2017)... Canada joint tech company Laughing Face has developed ... and features a powerful disinfection process. The company has ... and sanitizes women,s panties or babies, cloth diapers in 25 minutes. ... Laughing ... external water inlet. ...
Breaking Medicine Technology: